The T 258 imprint identifies a combination prescription pain relief tablet containing Hydrocodone Bitartrate (7.5 mg) and Acetaminophen (325 mg). Manufactured by Camber Pharmaceuticals, Inc., this medication belongs to the opioid analgesic combination class and is classified as a Schedule II controlled substance in the United States due to its significant potential for abuse, severe physical dependence, and addiction.
Physical Identification
Physical Parameter – Specification
- Active Ingredients – Hydrocodone Bitartrate (7.5 mg) + Acetaminophen (325 mg)
- Form – Solid oral tablet
- Shape – Capsule-shaped / Oblong
- Color – White to off-white
- Imprint – T 258 debossed on one side; plain on the other side with a score line (bisect)
- Drug Class – Opioid / Non-Opioid Combination Analgesic
- CSA Schedule – Schedule II (Controlled Substance)
- If you possess a pill with a different imprint, color, or shape, do not assume it contains hydrocodone and acetaminophen. Always consult a licensed pharmacist for visual identification.
Mechanism of Action
The T 258 tablet combines two active agents that operate through complementary pathways within the nervous system to relieve moderate to severe pain:
Hydrocodone Bitartrate (Semi-Synthetic Opioid)
- Receptor Activation: Hydrocodone acts as a selective agonist primarily at the opioid receptors in the central nervous system (CNS) and spinal cord.
- Pain Signal Inhibition: Binding to these receptors inhibits adenylate cyclase, closes presynaptic N-type voltage-gated calcium channels, and opens postsynaptic potassium channels. This hyperpolarizes neurons, blocking the transmission of ascending pain signals.
- Altered Perception: It modifies the emotional perception and psychological response to pain in the brain.
Acetaminophen (Non-Opioid Analgesic & Antipyretic)
- Central Prostaglandin Inhibition: Acetaminophen inhibits central cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS to elevate the overall pain threshold.
- Synergistic Analgesia: When paired with hydrocodone, acetaminophen enhances overall pain control without causing additional opioid-related sedation or respiratory depression.
Approved Indications & Usage
Hydrocodone Bitartrate and Acetaminophen 7.5 mg/325 mg is FDA-approved for the management of acute, severe pain in adults where alternative non-opioid options (such as NSAIDs or acetaminophen alone) are inadequate, not tolerated, or ineffective.
- Clinical Usage Boundary: Opioid combination drugs should be used at the lowest effective dose for the shortest necessary duration (typically a few days for acute post-surgical or traumatic pain).
Dosage Guidance
Dosage must be strictly individualized based on pain severity, patient weight, previous opioid tolerance, and kidney/liver health.
- Standard Adult Dosage: 1 tablet taken orally every 4 to 6 hours as needed for pain.
- Maximum Daily Limits:
- Acetaminophen Ceiling: Do not exceed 4,000 mg of acetaminophen per day from all combined sources (including over the counter cold medicines, fever reducers, or prescription drugs) due to the risk of fatal liver damage.
- Opioid Dosing: Never exceed the prescribed daily frequency or take double doses.
Side Effects
Common Side Effects
- Central Nervous System: Drowsiness, dizziness, lightheadedness, headache, and sedation.
- Gastrointestinal System: Nausea, vomiting, severe constipation, abdominal distress, and dry mouth.
- Dermatologic/General: Sweating, skin itching (pruritus), and feeling faint upon standing (orthostatic hypotension).
Serious & Severe Adverse Reactions
Seek emergency medical attention immediately if any of the following occur:
- Severe Respiratory Depression: Dangerously slow, shallow, or irregular breathing.
- Acute Hepatotoxicity (Liver Injury): Dark urine, yellowing of the skin or eyes (jaundice), severe fatigue, or severe pain in the upper right abdomen.
- Anaphylaxis / Severe Skin Reactions: Swelling of the lips, tongue, or throat, hives, or blistering skin reactions (e.g., Stevens-Johnson Syndrome).
- Adrenal Insufficiency: Long-term use can impair adrenal function, causing extreme weakness, nausea, low blood pressure, and loss of appetite.
Precautions & Boxed Warnings
FDA Boxed Warnings (Black Box)
- Addiction, Abuse, and Misuse: Risk of opioid use disorder, overdose, and death.
- Life-Threatening Respiratory Depression: Highest risk occurs during treatment initiation or following a dose increase.
- Accidental Ingestion: Ingestion of even one tablet by a child can be fatal.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can cause life-threatening opioid withdrawal in newborns.
- Hepatotoxicity: Acetaminophen is linked to acute liver failure, which can result in liver transplantation or death.
- Risks from Concomitant Use with Benzodiazepines or CNS Depressants: Co-administration with benzodiazepines, muscle relaxants, or alcohol causes profound sedation, coma, and fatal respiratory failure.
Key Precautions
- Avoid Alcohol Completely: Combining alcohol with T 258 significantly accelerates respiratory depression and drastically increases the risk of acute liver toxicity.
- Gradual Discontinuation: Do not abruptly stop taking this medication after prolonged or daily use. Sudden cessation causes physical withdrawal symptoms (e.g., severe anxiety, tremors, sweating, muscle pain, nausea, and rapid heart rate). Always taper under medical supervision.
- Impaired Driving and Reflexes: Do not operate heavy machinery or drive while taking this drug until you know how it affects your cognitive and motor function.